Original Investigation
November 2, 2022
Electroacupuncture vs Sham Electroacupuncture in the Treatment of Postoperative Ileus After Laparoscopic Surgery for Colorectal Cancer: A Multicenter, Randomized Clinical Trial
Yu Wang, Jing-Wen Yang, Shi-Yan Yan, et al
JAMA Surg. Published online November 2, 2022. doi:10.1001/jamasurg.2022.5674
Question In the current medical practice adopting the Enhanced Recovery After Surgery (ERAS) protocol, does electroacupuncture promote postoperative recovery in patients after laparoscopic bowel resection for colorectal cancer compared with sham electroacupuncture?
Findings In this randomized clinical trial of 248 patients, compared with sham electroacupuncture, electroacupuncture shortened the duration of postoperative ileus and reduced the incidence of prolonged postoperative ileus after laparoscopic resection of colorectal cancer, and no serious adverse events were reported.
Meaning Results of this trial show that electroacupuncture is effective in promoting gastrointestinal function recovery within the ERAS protocol.
Abstract
Importance Despite the adoption of the optimized Enhanced Recovery After Surgery (ERAS) protocol, postoperative ileus (POI) severely impairs recovery after colorectal resection and increases the burden on the health care system.
Objective To assess the efficacy of electroacupuncture (EA) in reducing the duration of POI with the ERAS protocol.
Design, Setting, and Participants This multicenter, randomized, sham-controlled trial was conducted in China from October 12, 2020, through October 17, 2021. There was a 1:1 allocation using the dynamic block random method, and analyses were by intention to treat. Patients 18 years or older undergoing laparoscopic resection of colorectal cancer for the first time were randomly assigned to treatment group by a central system.
Interventions Patients were randomly assigned to 4 sessions of EA or sham electroacupuncture (SA) after surgery. All patients were treated within the ERAS protocol.
Main Outcomes and Measures The primary outcome was the time to first defecation. Secondary outcomes included other patient-reported outcome measures, length of postoperative hospital stay, readmission rate within 30 days, and incidence of postoperative complications and adverse events.
Results A total of 249 patients were randomly assigned to treatment groups. After the exclusion of 1 patient because of a diagnosis of intestinal tuberculosis, 248 patients (mean [SD] age, 60.2 [11.4] years; 153 men [61.7%]) were included in the analyses. The median (IQR) time to first defecation was 76.4 (67.6-96.8) hours in the EA group and 90.0 (73.6-100.3) hours in the SA group (mean difference, −8.76; 95% CI, −15.80 to −1.73; P = .003). In the EA group compared with the SA group, the time to first flatus (median [IQR], 44.3 [37.0-58.2] hours vs 58.9 [48.2-67.4] hours; P < .001) and the tolerability of semiliquid diet (median [IQR], 105.8 [87.0-120.3] hours vs 116.5 [92.0-137.0] hours; P = .01) and solid food (median [IQR], 181.8 [149.5-211.4] hours vs 190.3 [165.0-228.5] hours; P = .01) were significantly decreased. Prolonged POI occurred in 13 of 125 patients (10%) in the EA group vs 25 of 123 patients (20%) in the SA group (risk ratio [RR], 0.51; 95% CI, 0.27-0.95; P = .03). Other secondary outcomes were not different between groups. There were no severe adverse events.
Conclusions and Relevance Results of this randomized clinical trial demonstrated that in patients undergoing laparoscopic surgery for colorectal cancer with the ERAS protocol, EA shortened the duration of POI and decreased the risk for prolonged POI compared with SA. EA may be considered as an adjunct to the ERAS protocol to promote gastrointestinal function recovery and prevent prolonged POI after surgery.
Trial Registration Chinese Clinical Trial Registry Identifier: ChiCTR2000038444
